Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Q3 press release...very encouraging.....
The Q3 2018 press release was extremely interesting. All indications suggest that VODG has finally turned the corner, with business activities ramping nicely, and potentially very interesting developments coming.
One thing I had hoped to see in this press release is management (either CEO Musick or CFO Evans) provide more information on the status of the filing delinquency. I can't stress enough how important it is for VODG to provide more transparency regarding this issue (see post above, for my concerns). The SEC seems to be getting more aggressive in its suspension/revocation activity (albeit, still inconsistent) in the last year. That continued threat to the stock has obvious influence/implications on the stock price and the safety of retail shareholder positions in this stock. Hopefully management will be very proactive in rectifying the delinquency, or at a minimum provide shareholders with a more detailed view of the situation.
Other than that, this press release was very encouraging. Some of the more interesting statements/comments in the PR centered around the guidance of being cashflow positive going forward, the cosmetic product, and IRBs that are currently under review in other countries......
Cashflow/Revenues: The statements/comments in the financial results section of the press release suggest/imply that VODG will probably be seeing $200+K revenue quarters going forward......
MAVT(.01)...Nevada filings updated.....
I picked up more shares this week (and over the last few months) to add to my position. SEC filings have been brought current. Nevada filings were updated over the last week (reflecting the management change, reverse split, and name change to "Viabuilt Ventures"). So it appears that everything is pretty much a "go" on this reverse merger getting completed and corporate activity should be increasing over the next few weeks/months.
https://www.nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=PJ3xL3WEx0vDBIBtVdqldg%253d%253d&nt7=0
Last quarterly report mentioned that a private placement is expected to occur with the merger. I continue to believe this price area looks extremely attractive for entry/accumulation, depending on some of the factors I mentioned in the post below......
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141652298
zjaye21...IBGH/QUBT, PLFM, Nutripy......
Hammer's statement appears on DVC website......
20-cent entry/accumulation area looks interesting......
I added a small amount recently in the low .20s for a possible short-term trading opportunity. IMO, the chances of seeing at least one nice pop/spike in the share price over the next month or two look pretty decent.
The last three press releases disclosing VODG's periodic earnings results have been issued around 2 months after the close of the fiscal quarter/year. Which means we should see the Q3 PR in roughly 3-4 weeks. In the absence of quarterly/annual filings, VODG seems to have taken the approach of making its press releases much more informative (more lengthy management commentary, interesting tidbits of information regarding its research/development, etc.). So every time you see a VODG press release hit the wires, there is a chance of seeing something that might cause a significant move in the share price.
If VODG has increased its financing placements to 20 cents (as per this Yahoo message board post a couple of weeks ago), that would seem to be a pretty good sign that we will be seeing higher prices down the road......
Life Sciences Biopharma...Louis Cona...cannaceuticals......
Interesting to note that Louis Cona (Medical Director of DVC Stem) is also the Chief Medical Officer of a relatively new company involved in the medicinal cannabis industry.
In the partners section of the DVC Stem website, you will notice that among the companies/organizations that DVC Stem is working with is a company called "Life Sciences Biopharma". The website for that company doesn't currently show much information beyond management and contact info, but you can find a very brief business description of the company here......
Michael Armand Hammer...possible endorsement of DVC Stem......
It probably wasn't noticed by very many people, but this morning DVC Stem posted on its Facebook page an endorsement by a very well-known businessman/philanthropist -- Michael Armand Hammer. It only appeared for less than an hour or so before the company apparently removed it.
From what I recall from the text of Hammer's statement, he had done research on various stem cell therapy clinics and ultimately chose DVC Stem for his stem cell treatment (which he received this year). According to Hammer his primary doctor(s) was pleased with the results, and Hammer recommended DVC Stem's services for anyone choosing that particular treatment route.
I'm not sure why DVC removed its post (maybe they posted it prematurely?), but it definitely was there this morning for at least 45 minutes to an hour.
https://en.wikipedia.org/wiki/Michael_Armand_Hammer
https://www.facebook.com/DVCStem/
George Sharp's involvement with EMPM......
One thing I would like to see George do is provide more clarification on exactly what his involvement with EMPM entails. For example, I would be curious to know if Sharp/EMPM have some sort of "official" agreement in place, whether EMPM is relying primarily or exclusively on Sharp to find and/or approve a RM candidate, and the nature/amount of any finder's fee that Sharp will receive.
EAD Law Group is EMPM's registered agent on its Nevada reinstatement filing (and perhaps EMPM's security counsel?). Ever since the EMPM reinstatement appeared (and before Sharp mentioned he had offered his services to the company), I have been assuming/guessing that EAD Law would be heavily involved in suggesting/picking a RM target for the EMPM shell. I figured the most likely RM target would probably be one of the many private companies that EAD Law Group has registered in Nevada during the last couple of years.
Some of those companies may go public through a direct registration process, but many will probably be future reverse merger candidates......
https://www.nvsos.gov/SOSEntitySearch/RACorps.aspx?fsnain=X81g5it%252bd1eRO42UpS7L%252bA%253d%253d&RAName=EAD+LAW+GROUP%2c+LLC
https://www.nvsos.gov/SOSEntitySearch/RACorps.aspx?fsnain=qLzmny0okzqfX%252bWqTcV%252bmw%253d%253d&RAName=EAD+LAW+GROUP%2c+LLC
BESE(.0032)...established a position.....
LWLW(2.00)...took a position in this shell.....
BLLZ(.025)...increased my position.....
Picked up a bunch more shares at 2 cents this morning, based on the apparent reverse merger that is taking place here. The June 17 press release on the BLLZ website went largely unnoticed, so I figured it might be a good idea to increase my position before the new CEO/company releases any official press release or makes a filing.
Definitely high-risk without knowing for sure what the final share structure will look like, or the financials of the RM target. But the BLLZ-related debt is being completely eliminated along with divesting the current business/operations. Since the Welch's control 90+% of the shares, the most ideal scenario here would be if the Welch family sold most (if not all) of their shares to the incoming RM company. I'm hoping and crossing my fingers that is what has happened here. That would leave a reasonably attractive share structure and leave potentially nice upside for the retail shareholders. Should be interesting to see how this plays out.
Some items of interest.....
1) Website: VODG's website has been offline for about 6-7 days. According to the company's Facebook page, the company is working on improving the e-commerce features of the site. I'm curious to see if there are any additional changes/upgrades to the site.
https://www.facebook.com/vitrodiaginc/
2) Fisher Scientific: When the website comes back online, it will be interesting to see if Fisher Scientific is still listed as a distributor of VODG products. Fisher first showed up in the "strategic partners" section of the website at the end of 2017 or very early 2018. But as far as I can recall, management has never made any public acknowledgement of that in any press release or filing. Having Fisher Scientific as a distributor is pretty big news, especially when you consider that VODG has relied primarily on in-house sales or just a couple/few small distributors over the years.
This is a cached page of VODG's website.....
https://webcache.googleusercontent.com/search?q=cache:gcD0iy4VVWoJ:https://vitrobiopharma.com/home/about/strategic-partners/+&cd=1&hl=en&ct=clnk&gl=us
3) The June 26 press release: Aside from the interesting information regarding the financial performance and financing-related activities, one thing that caused my eyebrow to raise a little bit with curiousity is that sentence in the "research and development" section of the PR.....
VODG...reply to private message....
To the person who sent me a private message regarding VODG......
I had posted on this board in June (if I recall correctly) but IHUB deleted the post shortly after it appeared, so I didn't bother to try again.
I still have my position, but it is admittedly difficult to continue holding the shares because the suspension/revocation risk might be increasing as every day goes by. Unfortunately, the company has put the retail shareholders in pretty much of a bind here with its public acknowledgement in the December 20, 2017 press release that it does not intend to maintain its reporting compliance.....
MRDH(.01)...subsidiary name change, wildcards, etc......
I continue to hold a large position in MRDH. High-risk investment without a doubt, but the "unusual" activity involving this stock/company (and its sister stock -- ICCO) over the last year or so continues to attract my attention. I don't know what is (or perhaps will be) occurring, but "something" certainly appears to be going on.
That activity, plus the potential wildcards of CEO Anthony Dike's still-active licensing agreements for NASA-related technologies, has me still holding tight to this position.
Some noteworthy things that have occurred over the last year.......
1) Anthony Dike filed a name change (MaxiCare Holdings Corporation) and address change with the Colorado SOS.
https://www.sos.state.co.us/biz/BusinessEntityHistory.do?&cmd=passgo&sc1=2
2) In mid-2017, Anthony Dike registered websites for MaxiCare and Vasocor (which is a medical device owned by ICCO).
3) ICCO had its OTC profile updated in January 2018. Although MRDH's profile page doesn't officially reflect it, I'm pretty sure its corporate address was updated on its OTC profile page around the same time.
4) MRDH has had a subsidiary called "Meridian Energy Corporation" registered in Colorado since 2005. In June 2018, Anthony Dike changed the name of that company to "SpectraCare Holdings Corporation".
https://www.sos.state.co.us/biz/BusinessEntityHistory.do?&cmd=passgo&sc1=2
Regarding the potential wildcards: Over the years Anthony Dike has entered into licenses/agreements to develop/commercialize NASA-related technologies. He usually does this through his private medical device research/development company (Meridian Health Systems, P.C.). One thing that has always intrigued me a little bit about MRDH/ICCO over the last few years is the possibility (perhaps remote) that Dike might use MRDH/ICCO to help commercialize any new devices/technologies from his private firm.
I've been monitoring the list of active Space Act Agreements that NASA puts out. As of the latest report (March 31, 2018), Meridian Health has two active agreements still in place. Both of them are set to expire in March 2019....
1) Annex 03 to MERIDIAN HEALTH SYSTEMS FOR
MICROWAVE TISSUE SOLDERING FOR WOUND
CLOSURE
2) Microwave Applications For Healthcare Treatments and
Radio Frequency Identification (RFID) Monitoring and
Tracking
https://www.nasa.gov/sites/default/files/atoms/files/active_domestic_nonfed_saas_house_approprs_action_as_of_3-31-2018.pdf
Given the pretty explosive share price movement that MRDH has shown in the past, if any of the wildcard plays came into play here, I think the market reaction would probably be quite interesting.
EMPM...my primary concern about the filing(s)......
I'm not 100% sure about this, but I think EMPM has made a mistake with its filings. And because of the amount of time that EMPM has been delinquent on its filings, they better get this corrected quickly.
I'm pretty sure that EMPM needed to file a Form 15-12G (to suspend its SEC filing obligations) before it filed the Form 10-12G.
If I am correct on this, I am a little surprised that this type of mistake would have been made since it appears that the company has some fairly competent people/entities working with it.
Based on the identity of the registered agent on the Nevada reinstatement, I am assuming that EAD Law Group is probably also acting as the securities counsel for EMPM. I don't know whether George Sharp has provided any advice/counsel on the filings or is just assisting with vetting reverse merger candidates.
EMPM(.006)...accumulated a position......
Accumulated a large position in the EMPM shell (or quasi-shell) last week. Extremely high-risk investment because of the filing delinquency and the overall valuation (market cap plus possible debt) of the shell is higher than I would prefer.
But if the company follows up its recent reinstatement with some filings, there could be some pretty decent upside from around this half-penny price level.
Somewhat interesting to note that the registered agent which handled EMPM's reinstatement (EAD Law Group) has registered more than 25 private companies in the last two years in the state of Nevada. That includes 7 just recently here in calendar 2018.
I haven't seen any speculation yet on what company/asset might be vended into the EMPM shell, but it wouldn't be surprising if it comes from that list of EAD-related Nevada companies. Some of those companies look like they could make for some interesting reverse mergers.
MAVT(.013)...increased my position.....
MAVT(.01)...possible Firetainment reverse merger.....
Finished adding to my MAVT shell position yesterday (currently have a cost basis around .007). Risk level is high due to the filing delinquency and any lingering negative market reaction to the upcoming 1:25 reverse split, but the risk/reward around this sub-penny to one-cent area continues to look pretty interesting to me.
I do have some concerns regarding exactly what happens to the $400+K debt that MAVT may still have on its books. The April 8-K regarding the proposed reverse merger with Firetainment did not specifically address this. I'm not sure if there will be any debt forgiveness, shares issued (either pre- or post-split) for the debt, or if Firetainment plans to absorb and pay off any remaining debt obligations.
But based on the disclosed terms of this RM, I think there might be some decent money to be made here. If I am interpreting the agreement correctly, the share structure could be relatively attractive (probably under 10M shares outstanding, with legacy shareholders retaining roughly 13% of the company). If in fact that is how the merger plays out, then a post-split price of 25-cents per share and an accompanying low market cap would seem to be particularly attractive.
According to an April 2017 article, Firetainment had a sales goal of $7 million for fiscal 2017, up from $2.5M in the previous year. Some excerpts from that article......
SEC's suspension policy does a disservice to investors.....
nvidiaforgames...GPLS.....
GPLS(.016)....possible website clock countdown.....
Picked up a few more shares of GPLS today. The sub-.02 shares look pretty interesting to me.
I'm a little bit puzzled/concerned about what exactly new CEO Marcus Laun is doing following the apparent reverse merger with his Growth Circle company. If in fact the RM is with Growth Circle (an IR/Media/Marketing company that provides services to a diversified list of clients/stocks), I'm not sure why the CEO has chosen to change the name of the company to Cannco Brands (a name that would suggest more of a focus on one specific industry -- marijuana-related companies). Not sure if he intends to completely shift the focus of the company to just MJ companies, or continue to service all companies.
But Marcus Laun is supposed to be a branding expert, so hopefully this move turns out well.
I'm not sure if the website link below is in fact associated with GPLS, but if it is I'm a little surprised that more Investors Hub traders and momentum groups haven't shown increasing interest lately in GPLS. Normally these website countdown clocks attract some trading interest. This website is scheduled to go active at the beginning of 2018.....
http://www.canncobrands.com/
IBGH(.004)...accumulated a position.....
I accumulated a position in the IBGH shell. Certainly a high-risk investment but the risk/reward around the .005 or lower levels looks reasonably interesting to me.
Attorney Angela Collette took control of the shell in August, and my guess is that some type of merger/acquisition activity will probably take place in this coming year. Some of the recent changes to the OTC profile (address, phone number, website, etc) over the last few weeks are somewhat confusing/concerning.
I'm not sure if the original change that highly suggested that IBGH would be doing a RM with Nutripy was simply an error or a premature release of information. But if there is a potential RM with Nutripy in the works, I think it would be a somewhat interesting company. Nutripy CEO Jeffrey Moore did a small equity-based crowd funding back in July of this year......
https://www.google.com/url?url=https://d19j0qt0x55bap.cloudfront.net/production/startups/nutripy/documents/offering_details/nutripy_offering_details__1_.pdf&rct=j&frm=1&q=&esrc=s&sa=U&ved=0ahUKEwjbn8aRkP_XAhVD7yYKHc_nCLM4ChAWCDwwCA&usg=AOvVaw0uNqjice6lluZBmBKCG3sD
There is also some possibility that Collette is preparing IBGH to be another shell for one of the client companies of William Alessi (connected to the LDSR shell). Perhaps that would lead to some type of cryptocurrency speculation. Certainly from a structural/valuation perspective, the IBGH shell would appear to be quite attractive compared to the multi-million dollar market cap of the LDSR shell.
tjvs/netmoney1999...BLLZ.....
BLLZ...added to my position.....
Accumulated some more BLLZ in the last couple of weeks or so. Appears to becoming a little more difficult to acquire large blocks of shares at the one cent level, so that might be an encouraging sign.
The market interest/environment for this stock could see a positive change if the CEO does follow through on a Nevada reinstatement and updated OTC filings.
Some of my concerns about the filings/disclosures......
I think a lot of investors (myself included) are probably waiting for additional weakness in the share price before any entry or additional accumulation.
I have already been burnt once before by an ASKH periodic filing (2014 10-K) that turned out to inaccurate. Management completely failed to disclose its October 2014 floorless convertible in that particular filing, and then to make matters even worse it did not disclose that debt until about one year later. Needless to say, that kind of managerial incompetence is completely unacceptable.
It would be somewhat tempting to pick up ASKH shares at sub-penny prices if we could be absolutely certain that the October 2014 debt is the only floorless convertible that ASKH has on its books, and we could be certain that management will not engage in any further financing of this nature.
What I want to see is full disclosure in an 8-K or the next periodic filing on a couple of items that are of concern to me......
1) The $22.5K debt owed to Artfield Investments is still sitting on the balance sheet and it is convertible into shares. It has now been more than 2 years, and ASKH still has not provided any details at all on the conversion terms of that debt.
2) The CEO should set exact repayment terms on the related party debt that the company owes to him, so there will be no unpleasant surprises if/when he decides to convert that debt into shares. The fact that the CEO loaned the company a large chunk of money, but decided not to pay off that toxic debt has me a little concerned that the CEO might decide to convert his debt at an extremely low price.
SEC's approach to suspension/revocation needs improvement......
Unfortunately, the SEC pretty much has a "We can do whatever we want, whenever we want" approach to stocks that are not trading on the big boards. That kind of attitude poses a great deal of danger for many of the stocks we are interested in, and also furthers the SEC's ultimate goal of ending all (or at least severely curtailing the number of) reverse mergers in the US market.
Quite a few years ago I recall one of the SEC's "underlings" did an interview regarding all the controversy surrounding the Chinese stocks and the problems with the audits. That person made a statement which made it pretty clear that the SEC has a deep-seated dislike for the whole idea of reverse mergers. Basically the SEC wants to force any company that wants to go public to take on an underwriter and go through an "IPO process", regardless of whether you actually needed or wanted to have an underwriter involved with company. It wouldn't be easy for the SEC to actually implement this policy because it would receive severe backlash from lawyers, companies, etc, but if it did get implemented it would have a pretty negative impact on the reverse merger and direct registration markets.
The current approach the SEC takes toward suspension/revocation of delinquent or dark tickers really does a disservice to the average retail investor. There is simply too much inconsistency and not enough adequate public disclosure of its policy and actions. It needs an overhaul.
There really is no excuse why the SEC can not conduct its suspension/revocation process completely in the open. Every investor should be given the opportunity (in real time) to know when the SEC has contacted a potential suspension/revocation target, exactly what the SEC is requesting/demanding of the company, any exact timelines for response/punishment the SEC has made, and any response the SEC has received from the company.
By not making full disclosure of all of this, the SEC potentially allows insiders/friends/associates of the company an opportunity to make a buy/sell decision while the average retail investor sits there in the dark unaware of what is going on behind the scenes. For an organization that is supposedly looking out for the "little guy", this is an completely unacceptable way to handle the situation.
Many of the opinions/statements I made in the post below on another board still stand today.....
MAVT(.0061)...picked up a position.....
PGUZ(.002)...worth monitoring for possible changes....
An extremely high-risk investment, but I'm still holding my position in PGUZ in case there is an upcoming change/addition to management or some other catalyst that might cause movement in the stock.
The CEO (Daniel Kesonen) passed away on August 4 from cancer (and I believe there was a stroke at some point, based on a social media posting I have seen). I would assume his health had been declining for much of 2017.
Kesonen had mentioned to other shareholders last year about the possibility of issuing an update/news around August/September of 2016. Kesonen seemed to make it clear that PGUZ was still actively involved in the areas of mold treatment and cardiac diagnostics. Obviously that update did not occur, but I did find it somewhat interesting that websites apparently closely associated with PGUZ's technologies had unusual update activity during 2016. For example, websites connected to PGUZ's MoldGuardian product had new images/pictures uploaded to those sites right around the time frame of June-August 2016.
PGUZ's annual filing for Nevada is due in about 2 months. Olof Hildebrand (who I believe is an active lawyer in Europe/Sweden) is the only other officer listed. So it should be interesting to see what happens when the Nevada deadline arrives. I am crossing my fingers that there were contingency plans put in place prior to Kesonen's death, and that Hildebrand or one of Kesonen's business associates will keep the company active in some form (either as a current operating company or a shell vehicle for a reverse merger).
http://www.legacy.com/obituaries/dignitymemorial/obituary.aspx?n=daniel-kesonen&pid=186304034
GSAC(.0033)...Mastix issued cannabis-related patent allowance.....
TVER(.0021)...purchased some shares....
It has been over 4 months since the management change at TVER. Investor interest in the stock has pretty much dropped off after that initial burst of interest/activity. I'm gambling/guessing this might be a good time to buy some shares.
I picked up some shares at .003 recently. This is probably at the upper limit of what I am willing to pay because there is suspension/revocation risk, and there was some unresolved debt still on the balance sheet at the time of its last filing in 2014.
All things considered, I figure the risk/reward at this level seems relatively reasonable.
MRDH(.0021)...might be worth monitoring.....
MRDH is an extremely high-risk investment, but it might be worth placing on a watch list just in case something is happening on the corporate level or in case the stock gets another push sometime this year. The stock has had some impressive/wicked swings in price over the last couple of years or so, and it would not surprise me if that type of movement occurs again.
A few weeks ago the OTC profile share structure was updated on both MRDH and its sister stock (ICCO). I think it has been 6+ years since the last time the structures were updated. MRDH's new number reflects about a 50M increase. I can't recall what ICCO's previous number was, but I think the new number is a similiar or slightly higher increase than MRDH.
Something that has caused my eyebrow a raise a little bit recently is the fact that during the month of June ICCO placed two job postings. One was for a sales representative and another was a general posting seeking business partners and distributorships. This was extremely unusual because in all the years that I have followed or owned MRDH/ICCO I have never seen the companies post any job listing on any mainstream job placement website.
Also, I am not 100% certain about this but a couple of months or so ago I remember checking on the California business status of ICCO and the database showed it as being "inactive". It now shows up as being "active".
MRDH's primary business activity involves managing a multi-state Accountable Care Organization, with the majority of its patients in Florida and California. The Centers for Medicare & Medicaid Services(CMS) releases ACO perfomance data for the previous year around August/September each year. The performance of each ACO is measured against its individual benchmark. While this data does not reflect the actual financial performance (revenue, net income, or net loss) of each ACO management company, it can give you some glimpse of how effective or ineffective the ACO has been.
I have had difficulty accessing the CMS database recently, so the numbers below are as best as I can remember when I checked on Meridian Health Systems ACO last year. The performance of MRDH's ACO has shown significant improvement over the last 3 years. It has gone from a negative $14M (2013), to a negative $5M (2014), to a positive $250K (2015). I don't recall what the total amount of medicare-related services that MRDH's ACO provided during 2015, but the number in 2014 was over $170M.
http://mhsaco.us/
CLCL...reply to private message....
To the person who sent me a private message regarding my current thoughts on CLCL......
I still own my position in CLCL, have added to that position, and might continue to add shares. But, having said that, I think the risk level of the stock has increased considerably since my last post.
Let me preface this by saying that I'm not aware of whatever (if anything) is happening behind-the-scenes on a corporate/management level, and whether those things (if any) would make those of us retail investors much more comfortable with our current positions in this stock. Hopefully my concerns will turn out to be overblown, but until we see some concrete positive corporate activity it is probably prudent to be at least somewhat alarmed/concerned with what is going on.
I'm not at all pleased with a number/variety of things regarding management (CEO Norm Kaplan) here. It is entirely possible that Kaplan never had any real intentions of updating the corporate and product website(s) as he had mentioned in his email last year. Kaplan allowed the registrations to the sites to expire and the corporate website was scooped up by one of those website "vulture" firms. If his intention going forward is to operate the company without any significant website presence, I think that is a huge strategic blunder on his part.
One of my concerns at the moment is whether Kaplan is truly committed to advancing the company and keeping the stock active/alive. The SEC's "pre-emptive strike" policy (in which the SEC seeks to suspend/revoke non-filing stocks) poses a potential serious threat to CLCL. The absence of an informational, fully-updated corporate website certainly doesn't help the situation.
If the SEC does contact CLCL and makes its usual requests/demands, I just don't know if Kaplan would have the ability or willingness to actually satisfy the SEC's demands. I don't know if Kaplan fully understands/appreciates the danger he is placing the stock in by not taking at least some minimal actions/efforts that might help avoid having the SEC suspend/revoke CLCL's registration, for example: get the OTC profile fully updated, some filings, etc., etc.
The upside potential from these price levels could be substantial, but there is also a very real possibility that any continued/additional investment in CLCL could end up being just a complete waste of time/money.
BLLZ(.015)...added more to my position.....
Picked up another large block of shares at .01 a couple of weeks ago.
BLLZ(.01)..March 30 PR, accumulated position.....
Finished accumulating a position in the sub-penny to penny level over the last few weeks. Was pretty difficult to purchase any sizable blocks under the .006 level, so decided to pick up some larger blocks around this one-cent area. Looks like the stock could be capable of some explosive swings/moves in the share price under the right situations.
Thought it might be wise to be pre-positioned ahead of a possible reinstatement, OTC profile/filings update, and increased corporate actions (including divesture/acquisition activity). BLLZ also is a bit interesting at this point because it is a lesser-known play in the cyber security area of the market.
The March 30 press release.....
VODG(.135)...corporate activity expected to increase.....
I'm expecting to see a significant increase in corporate activity and a more robust approach to investor relations at VODG following a successful closing on the proposed $1.7 million financing. As per the recent press release and 8-K filing, the company should regain SEC compliance and there will be changes/additions to management and the Board of Directors.
The person/entity that is providing the $1.7M financing is prepared (if necessary) to loan/invest an additional $6.6M in VODG. But with a new CFO expected to officially come on board, I wouldn't be surprised if VODG starts attracting additional financing(s) from third parties.
It appears the proposed activity/transactions outlined in the release/filing have been under development for at least 8+ months, since the VODG CEO registered the website for the company's new subsidiary (Halo Cell Sciences) back in August 2016. The website came online last week with the "Website Coming Soon" sign.....
http://www.halocellsciences.com/
VODG...upcoming major corporate developments.....
GSAC(.0033)...cannabis IP, contract manufacturing......
Added a few more shares to my position. GSAC continues to be a largely under-followed sub-penny play with connections to the cannabis sector. GSAC's involvement in the cannabis sector comes in the form of its contract manufacturing business (gum, lozenges, confectionery products, etc), pending patents on its manufacturing processes, and its own proprietary brands of CBD-infused products.
The stock is trading at a pretty steep discount to the 7 cent share price it was trading at when it acquired Mastix Medica in 2014.
PGUZ(.0042)...Amgen, Cannabis mold prevention, etc.....
Accumulated a position in PGUZ (mostly at .004/shr) over the last few months. Definitely a high-risk investment for a number/variety of reasons, but the risk/reward around this price level looks intriguing. There has been some interesting activity on websites during 2016 that may have direct/indirect connections to products or technologies that have been associated with PGUZ.
One thing I would like the CEO to do is provide a very clear/detailed picture of PGUZ's current relationship/connection to the primary product/technology areas it is (or has been) involved with (anti-fungal products and the cardiac screening device/tech). That includes ownership rights, transfers of ownership, any licensing deals entered into, distribution deals, joint ventures, equity positions that PGUZ may have received from currently private companies, etc., etc. The reason I would like to see this type of clarification is because Google searches on the company and its technologies leads to a somewhat confusing/conflicting picture.
For example: It appears fairly clear that VE Science Technologies has some involvement in PGUZ's cardiac screening product/technology. I'm not sure whether it is because that company now owns the tech or whether it is from some type of licensing/distribution/marketing deal with PGUZ. In February 2016, VE Science sold the product distribution rights to Odyssey Group International......
http://www.cardiomap.com/
http://theodysseygroupinternational.com/?page_id=65
Despite all the confusion and risks involved, I decided to take a position because if PGUZ does still maintain significant business/financial interests in the above product areas this stock could have some explosive potential based on some of the updates of websites related to the anti-fungal product(s).
To the best of my knowledge, it has never been publicly-disclosed before that large pharma/biotechs like Amgen and Celgene have been using PGUZ's anti-mold product (MoldGuardian)......
OODH(.0025)...accumulated some shares.....
Picked up some shares in case this stock gets a push/promotion in 2017. Recent tweet by the CEO (yesterday) suggests that the Nevada filings will be updated soon, and a corporate update is expected at some point based on the CEO's tweets and the company website......
ECGI...CEO resignation, increased my position.....
I picked up some more shares last week at .0147 following CEO John Bentivoglio's resignation. Not sure if I am throwing good money at a bad situation at this point, but decided to increase my position just in case his resignation marks a bottoming out of the stock somewhere around this 1-2 cent area.
The company has not yet provided investors with any explanation/update as to what is going on. Implications for investors could range anywhere from extremely negative to extremely positive.
I can envision some scenarios here where this change in management of ECGI could turn out to be a favorable move for the shareholders. Gary Blom (from Main Street Capital, an Australian financial services firm) has been appointed Director (and interim CEO?). Blom has a lot of connections in the Australian/Asian markets, and I think his firm has represented the Australian investors/people that have been involved with ECGI (including MedPac Asia Pacific, Julie Singleton, etc.)
Assuming the resignation was not health-related, maybe the change in management is something that the Australian parties have been seeking/requesting.
http://mainstreetcapital.com.au/